A number of other equities research analysts also recently commented on AZN. Barclays reiterated an overweight rating and issued a GBX 5,500 ($74.02) price objective on shares of AstraZeneca in a report on Monday, August 7th. set a GBX 4,100 ($55.18) price objective on AstraZeneca and gave the company a sell rating in a report on Tuesday, August 8th. Investec upgraded AstraZeneca from a hold rating to a buy rating and dropped their price objective for the company from GBX 5,000 ($67.29) to GBX 4,900 ($65.95) in a report on Wednesday, August 9th. J P Morgan Chase & Co set a GBX 4,200 ($56.53) price objective on AstraZeneca and gave the company a neutral rating in a report on Wednesday, August 9th. Finally, Goldman Sachs Group set a GBX 3,900 ($52.49) price objective on AstraZeneca and gave the company a sell rating in a report on Friday, August 18th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company. AstraZeneca presently has a consensus rating of Hold and a consensus price target of GBX 5,169 ($69.57).
AstraZeneca (AZN) opened at GBX 4,704 ($63.31) on Monday. AstraZeneca has a twelve month low of GBX 3,996 ($53.78) and a twelve month high of GBX 5,520 ($74.29).
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
What are top analysts saying about AstraZeneca PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca PLC and related companies.